173 related articles for article (PubMed ID: 12007573)
1. Reversal of cisplatin resistance in human ovarian cancer cell lines by a c-jun antisense oligodeoxynucleotide (ISIS 10582): evidence for the role of transcription factor overexpression in determining resistant phenotype.
Pan B; Yao KS; Monia BP; Dean NM; McKay RA; Hamilton TC; O'Dwyer PJ
Biochem Pharmacol; 2002 May; 63(9):1699-707. PubMed ID: 12007573
[TBL] [Abstract][Full Text] [Related]
2. Evidence for altered regulation of gamma-glutamylcysteine synthetase gene expression among cisplatin-sensitive and cisplatin-resistant human ovarian cancer cell lines.
Yao KS; Godwin AK; Johnson SW; Ozols RF; O'Dwyer PJ; Hamilton TC
Cancer Res; 1995 Oct; 55(19):4367-74. PubMed ID: 7671249
[TBL] [Abstract][Full Text] [Related]
3. [Study of bcl-2 antisense oligodeoxynucleotides on reversal of cisplatin resistance in ovarian cancer cell line A2780/DDP].
Li M; Yu LL; Cai LQ; Wang HB; Wang ZH; Wang ZH
Zhonghua Fu Chan Ke Za Zhi; 2006 Feb; 41(2):121-5. PubMed ID: 16640863
[TBL] [Abstract][Full Text] [Related]
4. Increased DT-diaphorase expression and cross-resistance to mitomycin C in a series of cisplatin-resistant human ovarian cancer cell lines.
O'Dwyer PJ; Perez RP; Yao KS; Godwin AK; Hamilton TC
Biochem Pharmacol; 1996 Jul; 52(1):21-7. PubMed ID: 8678904
[TBL] [Abstract][Full Text] [Related]
5. Recovery of miR-139-5p in Ovarian Cancer Reverses Cisplatin Resistance by Targeting C-Jun.
Jiang Y; Jiang J; Jia H; Qiao Z; Zhang J
Cell Physiol Biochem; 2018; 51(1):129-141. PubMed ID: 30439707
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of Gli1 results in altered c-Jun activation, inhibition of cisplatin-induced upregulation of ERCC1, XPD and XRCC1, and inhibition of platinum-DNA adduct repair.
Kudo K; Gavin E; Das S; Amable L; Shevde LA; Reed E
Oncogene; 2012 Nov; 31(44):4718-24. PubMed ID: 22266871
[TBL] [Abstract][Full Text] [Related]
7. Cisplatin-induced apoptosis proceeds by caspase-3-dependent and -independent pathways in cisplatin-resistant and -sensitive human ovarian cancer cell lines.
Henkels KM; Turchi JJ
Cancer Res; 1999 Jul; 59(13):3077-83. PubMed ID: 10397248
[TBL] [Abstract][Full Text] [Related]
8. Effect of lung resistance-related protein on the resistance to cisplatin in human ovarian cancer cell lines.
Wang W; Ke S; Chen G; Gao Q; Wu S; Wang S; Zhou J; Yang X; Lu Y; Ma D
Oncol Rep; 2004 Dec; 12(6):1365-70. PubMed ID: 15547764
[TBL] [Abstract][Full Text] [Related]
9. Cellular glutathione level does not predict ovarian cancer cells' resistance after initial or repeated exposure to cisplatin.
Nikounezhad N; Nakhjavani M; Shirazi FH
J Exp Ther Oncol; 2017 May; 12(1):1-7. PubMed ID: 28472558
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
[TBL] [Abstract][Full Text] [Related]
11. Oridonin effectively reverses cisplatin drug resistance in human ovarian cancer cells via induction of cell apoptosis and inhibition of matrix metalloproteinase expression.
Ma S; Tan W; Du B; Liu W; Li W; Che D; Zhang G
Mol Med Rep; 2016 Apr; 13(4):3342-8. PubMed ID: 26935490
[TBL] [Abstract][Full Text] [Related]
12. Induction of gamma-glutamyl transpeptidase mRNA by platinum complexes in a human ovarian carcinoma cell line.
el-akawi Z; Zdanowicz J; Creaven PJ; Abu-hadid M; Perez R; Pendyala L
Oncol Res; 1996; 8(10-11):415-23. PubMed ID: 9114434
[TBL] [Abstract][Full Text] [Related]
13. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
[TBL] [Abstract][Full Text] [Related]
14. Interference with the expression of β-catenin reverses cisplatin resistance in A2780/DDP cells and inhibits the progression of ovarian cancer in mouse model.
Zhao H; Wei W; Sun Y; Gao J; Wang Q; Zheng J
DNA Cell Biol; 2015 Jan; 34(1):55-62. PubMed ID: 25211326
[TBL] [Abstract][Full Text] [Related]
15. Down-regulation of Ras-related protein Rab 5C-dependent endocytosis and glycolysis in cisplatin-resistant ovarian cancer cell lines.
Jin L; Huo Y; Zheng Z; Jiang X; Deng H; Chen Y; Lian Q; Ge R; Deng H
Mol Cell Proteomics; 2014 Nov; 13(11):3138-51. PubMed ID: 25096996
[TBL] [Abstract][Full Text] [Related]
16. [Relationship between cytochrome c-mediated caspase-3 activity and chemoresistance in cisplatin-resistant human ovarian cancer cell lines].
Yang X; Zheng F; Xing H; Gao Q; Wang W; Lu Y; Wang S; Ma D
Zhonghua Zhong Liu Za Zhi; 2002 Nov; 24(6):544-7. PubMed ID: 12667321
[TBL] [Abstract][Full Text] [Related]
17. Influence of the proto-oncogene c-fos on cisplatin sensitivity.
Moorehead RA; Singh G
Biochem Pharmacol; 2000 Feb; 59(4):337-45. PubMed ID: 10644041
[TBL] [Abstract][Full Text] [Related]
18. Downregulation of vimentin expression increased drug resistance in ovarian cancer cells.
Huo Y; Zheng Z; Chen Y; Wang Q; Zhang Z; Deng H
Oncotarget; 2016 Jul; 7(29):45876-45888. PubMed ID: 27322682
[TBL] [Abstract][Full Text] [Related]
19. [Chemotherapy resistance induced by interleukin-6 in ovarian cancer cells and its signal transduction pathways].
Wang Y; Li LZ; Ye L; Niu XL; Liu X; Zhu YQ; Sun WJ; Liang YJ
Zhonghua Fu Chan Ke Za Zhi; 2010 Sep; 45(9):691-8. PubMed ID: 21092551
[TBL] [Abstract][Full Text] [Related]
20. The role of expression of the components of proteome in the formation of molecular profile of human ovarian carcinoma A2780 cells sensitive and resistant to cisplatin.
Chekhun VF; Lukyanova NY; Urchenko OV; Kulik GI
Exp Oncol; 2005 Sep; 27(3):191-5. PubMed ID: 16244579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]